Toggle light / dark theme

A woman in Pittsburgh has become the first documented case in a living person of an unusual medical condition where alcohol naturally brews in the bladder from the fermentation of yeast.

The condition, which researchers propose to call either ‘bladder fermentation syndrome’ or ‘urinary auto-brewery syndrome’, is similar to another incredibly rare condition, auto-brewery syndrome, where simply ingesting carbohydrates can be enough to make you inebriated, even without consuming any alcohol via regular means.

In the case, doctors became aware of what seems to be a related syndrome, after attending upon a 61-year-old patient who presented with liver damage and poorly controlled diabetes.

From China’s theft of intellectual property, including “one in five corporations saying China has stolen their intellectual property within the last year;” to Chinese influence and espionage in academia as exemplified by the recent criminal complaint against the Chair of the Harvard Chemistry and Biology Department; to Chinese investment in U.S. tech with “Chinese investor-backed deals with U.S. tech startups jumping as much as 185-percent” — China’s strategy has been fully exposed.

Retired Admiral William McRaven probably had it right when he said this is a “holy s— moment” for the United States.

U.S. policymakers now see China’s strategy for what it is — a not-so-subtle attempt to influence and ultimately control U.S. tech. The government of China has been engaged in a deliberate campaign to re-orient U.S. technology companies towards China.

As there has been a considerable increase of questions, BioGaia has summarized the scientific information about the SARS-CoV-2 virus and the possible role of probiotics in the current COVID-19 global outbreak.

• Could probiotics protect against SARS-CoV-2 virus infection and aid in avoiding COVID-19? • Could probiotics help our immune system to prevent or potentially fight Coronavirus infections? • What are the scientific facts and the credible sources?

Please find below a summarized and updated information about this topic. Please note that to date, the scientific information we have regarding the current COVID-19 outbreak in terms of viral transmission, physiopathology and disease control is still preliminary and might change as time passes and more information becomes available.

Feline Coronavirus (FCoV) is a common viral infection in cats. It generally causes asymptomatic infection, but can cause mild diarrhea. As yet poorly understood changes in the virus can give rise to mutants that lead to the development of feline infectious peritonitis (FIP). Most cats infected with a FCoV eliminate virus following infection, but some cats may develop a persistent infection. These cats are generally asymptomatic, can shed large amounts of virus in feces, and serve as a continual source of infection for other cats in the environment. Continual circulation of FCoV within a cat population may increase the chance that a virulent FIP strain might emerge. While the pathogenesis of FIP is poorly understood, it is now believed that detection and removal of persistently infected and shedding cats in a multi-cat household can reduce the risk of FIP emergence within that population.

In response to the increased interest within the cat breeding and cat owning community, the Animal Health Diagnostic Center at Cornell University now offers a fecal RT-PCR test for FCoV. This test can be used to identify asymptomatic FCoV shedding cats so steps can be taken to isolate them from other cats or to prevent their introduction to a resident population. Samples required for the fecal RT-PCR screening test are 2–5 grams fresh feces. When screening an individual cat in a multi-cat household it is important to positively identify the source of the fecal sample. Mixing of fecal samples from multiple cats may result in an inaccurate result. Feces should be stored in a clean plastic bag to prevent dehydration.

In clinical FIP suspect cats, the test can also identify FCoV in ascites fluid, whole blood, plasma, serum or fresh tissues (kidney, liver, or spleen). Samples from FIP-suspects should include 1–2 ml of fluid (ascites, whole blood, serum, or plasma) or 1–2 grams of fresh tissues.

American oncologists are rushing to prioritise the patients at greatest risk, institute new protections, and learn from their collective experiences, Bryn Nelson reports.

A patient in Washington, newly diagnosed with breast cancer, fought to get her lumpectomy surgery rescheduled after it was cancelled indefinitely. 1 A stuffy nose required another patient in Massachusetts with a recurrent brain tumour to undergo multiple layers of screening before he could receive his immunotherapy infusion. 2 A patient with bladder cancer in North Carolina couldn’t get immunotherapy at all because of a lack of surgical masks and gloves. 3 Then he was denied a surgical alternative because he needed a covid-19 test first. Since he hadn’t been admitted to a hospital with serious covid-19 symptoms, he didn’t meet the testing criteria.

Covid-19 has wreaked havoc on cancer care throughout the US as medical centres scramble to cancel or rearrange surgeries or treatments, tackle a continuing shortage of tests and supplies, and devise new safety protocols to protect a highly susceptible patient group.

In an effort to find an effective antiviral drug against SARS-CoV-2. Calibr, the drug development division of Scripps Research, is leveraging a unique resource—the ReFRAME drug collection. The ReFRAME drug collection comprises over 14,000 compounds that have been approved by the FDA for other diseases. A medicine identified from this resource could be rapidly repurposed.